BOSTON, Dec. 17, 2025 — CranioSense, Inc., a neurotechnology company developing the world’s first noninvasive intracranial pressure (ICP) diagnostic and monitoring system, today announced the award of approximately $5.5 million in total non-dilutive funding through the NIH Blueprint MedTech Program and the U.S. Department of Defense’s Joint Warfighter Medical Research Program (JWMRP).
“In over a decade of working to develop Prolonged Casualty Care (PFC) training, doctrine, and equipment, one of the biggest gaps in monitoring critical casualties in austere military and civilian environments has been the inability to effectively track intracranial pressure,” said LTC (Ret.) Doug Powell, MD, former PFC consultant to the U.S. Army Special Operations Command (USASOC) Surgeon’s Directorate. “Noninvasive ICP monitoring has long been considered a ‘Holy Grail’ of PFC, and CranioSense’s work represents a meaningful step toward closing that gap.”
Together, these grants fund initiatives that will directly link CranioSense’s defense-driven work to its mission of improving brain pressure assessment across all levels of civilian care.
“These awards will support device development and pivotal validation, moving CranioSense decisively toward market launch,” said Ryan Myers, PhD, MBA, Chief Executive Officer and Co-Founder of CranioSense. “The Blueprint MedTech and JWMRP programs represent two sides of the same mission: enabling better neurologic care anywhere and everywhere it is needed.”
CranioSense’s technology uses near-infrared optical sensors and proprietary algorithms to deliver real-time, noninvasive diagnosis of elevated brain pressure. Once FDA-approved, the system will make intracranial pressure assessment as routine as blood pressure measurement, bringing much-needed diagnostic support to emergency departments, where rapid decisions matter most. In the future, the platform will measure additional biomarkers tied to acute and chronic brain health, unlocking AI-driven prediction and decision support to guide clinical care.
Leveraging complementary investments made in the Spring of 2025 by multiple angel investors, Illinois Venture Angels, She’s Independent, Heinz Ventures, and Hillside Ventures, the company will continue collaborating with leading clinical and engineering partners to achieve regulatory milestones and prepare for pilot deployment.
About CranioSense CranioSense, Inc. is a Massachusetts headquartered neurotechnology company developing noninvasive tools to monitor intracranial pressure. Founded in 2023, CranioSense’s mission is to make brain pressure monitoring as safe, simple, and universal as blood pressure measurement.
In its 12th year, the program achieved a record $1.5 million raised for the future of agriculture
PRAIRIE DU SAC, Wis., Dec. 17, 2025 — When Culver’s launched its Thank You Farmers Project in 2013, the goal was simple: support the agricultural community and show gratitude to the farmers who feed us. That mission has always included uplifting agricultural education and supporting the caretakers of our land to ensure a viable food supply for years to come. Today, Culver’s is proud to celebrate a record milestone: $8 million in total donations since the program’s inception.
Culver’s Thank You Farmers Project has officially passed $8 million in total donations since the program began in 2013.
In 2025 alone, thanks to the generosity of guests and local fundraising efforts, more than $1.5 million was raised to benefit the future of agriculture. Culver’s remains committed to strengthening farming for future generations through meaningful partnerships and active community involvement.
“Behind every meal we serve in our restaurants are local hardworking farmers,” said Alison Demmer, Culver’s senior public relations manager. “This year and every year, we’re proud to work alongside our guests to create something truly meaningful, and we’re so thankful to everyone who joined us in furthering our efforts to uplift our next generation of farmers.”
The success of the Thank You Farmers Project relies heavily on the generosity of Culver’s guests, who contribute through donations and participation in special events. Some of the ways that Culver’s and its communities have supported the Thank You Farmers Project this year include:
Green and Gold: Culver’s donated $1 for each rental and digital purchase of the movie “Green and Gold,” for a total of $100K to three agricultural organizations.
To Farmers with Love: Hundreds of guests nominated farmers and ranchers for the 2025 “To Farmers with Love Contest,” which rewarded five winners with a $500 cash prize, a VIP Tim McGraw concert experience at the iconic Field of Dreams, Culver’s gift cards and swag.
Scoops of Thanks Day: Guests donated over $170K in the 11th annual Scoops of Thanks Day fundraiser. The fundraiser offered guests the opportunity to get a single scoop of Fresh Frozen Custard in exchange for a $1 donation to local FFA chapters and other agricultural education organizations.
Concretes for a Cause: Culver’s raised more than $570K through Concretes for a Cause by donating $1 from each Concrete Mixer sold systemwide over a five-day period to local hunger relief initiatives.
Culver’s FFA Ambassadors: Guests nominated standout FFA members in their communities to represent Culver’s as FFA Ambassadors and earn prizes for their local chapter. Ten ambassadors earned up to $2,500 to fund learning experiences by participating in agriculture advocacy events in partnership with Culver’s.
Guests can discover more about the impact Culver’s Thank You Farmers Project has had on the future of agriculture since its creation through this infographic.
About Culver’s: For over 40 years, Culver’s guests have been treated to cooked-to-order food made with farm-fresh ingredients and served with a smile. The ever-expanding franchise system now numbers over 1,000 family-owned and operated restaurants in 26 states. The restaurants’ nationally recognized customer service is based on small-town, Midwestern values, genuine friendliness and an unwavering commitment to quality. Signature items include the award-winning ButterBurger, made from fresh, never-frozen beef, and Fresh Frozen Custard, including the famous Flavor of the Day program. For more information, visit www.culvers.com or connect with Culver’s on Facebook, Instagram and TikTok.
The funding will propel the already profitable company to expand their reach beyond their existing 6000+ clients
SAN FRANCISCO, Dec. 17, 2025 — Arcads.ai, the go-to platform for creating high-performing marketing videos with AI, today announced a round of 16 million dollars in Seed funding led by Eurazeo, with participation from Alpha Intelligence Capital and other international investors including the Sequoia Scout program.
Founded in 2024 by Dylan Fournier and Romain Torres, Arcads.ai is an AI platform that enables marketing teams to produce social-ready videos in minutes: The platform supports multiple high-performing formats — UGC-style AI actors, product demos, fashion try-on videos and unboxing content — available in more than 35 languages. Arcads.ai is now used by thousands of companies worldwide, from app studios and consumer brands to marketing agencies and individual founders.
An entrepreneurial story born from a frontline need
Before Arcads.ai, the two founders had launched a marketing agency, then a mobile app studio that generated several successes. With each launch, the same challenge arose: producing thousands of videos for social media in ultra-competitive environments, without resources comparable to large marketing teams.
Experiencing this structural pain point firsthand led Fournier and Torres to develop Arcads.ai. Within a few months and with a team of seven people, the company has already demonstrated rapid execution and strong traction with over 6,000 clients and 100,000 assets per month. Their mission remains the same: to make fast, scalable, and quality video production accessible, whether it’s for a studio generating millions of dollars or creators without a camera or internal resources.
Accelerating platform development and international presence
More than half of Arcads.ai users today come from the United States. This financing will allow the company to accelerate its growth by: the development of its platform, the broadening of its video generation capabilities, and by strengthening its international presence with an office in San Francisco.
“We created Arcads.ai to break down the barriers that exist when marketing teams need to quickly and affordably create the many videos needed to promote a product. We, ourselves, experienced this difficulty for years. With Arcads.ai, we are making this process accessible, simple, and iterative: test, adjust, repeat,” said Dylan Fournier, co-founder & Co-CEO of Arcads.ai. He continued, “The results already speak for themselves, we’re already profitable and this funding will give us the means to accelerate our development and support the growth of our user base, particularly in the United States.”
“In almost all the markets we follow, the battle is now played out in distribution, making one’s brand and product known. Arcads.ai gives marketing teams a structural advantage in this competition for attention, and the international traction we are observing confirms it. We are happy to accompany Arcads.ai in this new stage,” added Thomas Turelier, Managing Director, Venture Digital, Eurazeo.
Arcads.ai is a French company specializing in the automated generation of marketing videos from AI actors. The platform helps marketing teams, app studios, brands, and entrepreneurs quickly produce videos adapted for social networks, acquisition campaigns, and localization needs. Founded in 2024, Arcads.ai now supports over 6,000 clients worldwide. For more information, visit Arcads.ai.
About Eurazeo
Eurazeo is a leading European investment group managing 37.4 billion euros in diversified assets, including 28.0 billion on behalf of institutional and private clients through its private equity, private debt, real estate, and infrastructure strategies. The Group supports more than 600 Mid-Market companies, providing their development with the commitment of its 400 employees, its sectoral expertise, and its privileged access to global markets via its offices in Paris, New York, London, Frankfurt, Berlin, Milan, Stockholm, Madrid, Luxembourg, Shanghai, Seoul, Singapore, Tokyo, and São Paulo.
RESEARCH TRIANGLE PARK, N.C. and NEWPORT BEACH, Calif., Dec. 17, 2025 — ClinTrial Research (CTR) announced today that it has closed a growth equity round led by Tarsadia Investments, a multi-billion-dollar firm that makes high-conviction investments in category-defining companies globally. The investment reflects Tarsadia’s conviction that CTR is positioned to become the leader in the clinical site network sector.
“We fully believe in CTR’s mission to build the industry’s most trusted clinical site network—one that brings together exceptional people, advanced technology, and strong therapeutic leadership to elevate patient care and drive lasting innovation,” said Rishi Reddy, Managing Director and Head of Venture and Growth Equity at Tarsadia.
CTR CEO Sam Searcy emphasized that the partnership is far more than a capital infusion. “This investment from Tarsadia is a powerful vote of confidence from a respected industry leader with significant financial and strategic resources. It reinforces CTR’s position as a category-defining business,” Searcy said. “From our first meeting with the Tarsadia team last summer, the cultural alignment was immediate. It felt like speaking with close colleagues—effortless, natural, and an extension of our own team. Their intellectual depth and strategic insight are exceptional.”
The need for high-performing clinical site networks continues to grow. More than 90% of physicians who participate in a clinical trial never conduct a second one. When combined with staffing shortages, increasingly complex study protocols, and rising drug development costs, the importance of efficient, well-structured site networks becomes even more critical. “A site network that can solve across these four industry challenge areas will become a lasting and essential part of the pharmaceutical development ecosystem,” Searcy added. “We are confident we are building exactly that—approaching each challenge with precision, innovation, and the right long-term strategy.”
Reddy noted that CTR stood out clearly among companies evaluated. “CTR is led by a seasoned team who brings a modern, innovative approach to site networks and site management,” he said. “Critically, CTR and Tarsadia are aligned in their focus on bespoke AI-enabled technology platforms and the transformative impact they can have on the site network sector. Tarsadia invests with conviction in companies we believe are shaping the future and positioned for significant growth. After more than two years of analyzing the site network landscape, CTR was the team that checked every box for us: innovative, collaborative, AI-forward, and agile in a rapidly evolving market.”
SAN FRANCISCO, Dec. 17, 2025 — Tokenfolio, an active growth stage and pre-IPO tech investor, has been ramping up their institutional arm to better serve increasing demand from institutional investors to access top AI investments.
Tokenfolio are early investors in most of the top 10-15 high-profile AI startups in Silicon Valley and are currently focusing on investing early in what will become the top private market names of tomorrow. Tokenfolio typically invests in Series B through pre-IPO.
Their portfolio includes some of the top tech companies in AI infrastructure, AI robotics, and deep tech AI – for many of these, they joined highly oversubscribed funding rounds co-investing with world’s top funds like Sequoia, Lightspeed, Amazon founder Jeff Bezos (Bezos Expeditions), sovereign wealth funds and more.
Currently, reputed billionaire families in APAC, senior tech leaders, entrepreneurs with successful exits, and regulated funds invest with Tokenfolio. Beyond investments, Tokenfolio works closely with their portfolio companies to help them expand, especially across APAC given their active network and experience.
“Given increasing demand from our institutional LPs, it’s our key focus to ensure we can continue to follow industry leading processes as we scale. For this, we’re actively ramping up our efforts including partnering with market leaders to provide our LPs with best in class structures and services,” said Abhishek Malik, co-founder and CEO.
Most recently, Tokenfolio partnered with Carta in order to provide their investors with institutional grade fund administration services. Carta is one of the largest fund administrators in the world with over $180B assets under administration and 2,000 employees across 14 offices worldwide, and is uniquely positioned to service Tokenfolio’s global client base. Carta will serve as an independent third party fund administrator for Tokenfolio vehicles. Carta is backed by some of the largest VC funds, private equity funds and investment managers in the world, including a16z, Silver Lake and ICONIQ Capital.
Carta’s Dinesh Manivannen, Account Executive from their Funds team, said, “We’re excited to partner with Tokenfolio. Their rapid growth is impressive, we have the right expertise and tools to support them and their LPs as they keep scaling further.”
Abhishek added, “Appointing Carta confirms our commitment to delivering the most trusted, safe and robust way for investors to access some of the world’s best AI and deep tech investment opportunities across growth stage and pre-IPO investing.”
Tokenfolio’s move to Carta is a step towards ensuring its investors receive the same rigor, transparency and auditability previously reserved for large public market investors.
About Tokenfolio
Tokenfolio is a growth stage AI and deep tech investor that provides access to top Silicon Valley tech companies. An early investor in most of the top 10-15 high-profile AI startups, with a key focus on disciplined underwriting, Tokenfolio aims to invest today in companies that become the top private market names of tomorrow.
MUSCAT, Oman, Dec. 17, 2025 — Future Fund Oman announced record activity in 2025, approving 141 projects this year and lifting total commitments to $1.2 billion as the fund accelerates Oman’s economic diversification agenda. Established by Oman Investment Authority with a capital commitment of $5.2 billion to be deployed over five years, the fund is now one of the region’s fastest-expanding national investment vehicles, with all capital directed toward projects inside Oman and aligned with the priorities of Oman Vision 2040.
FUTURE FUND OMAN COMMITS $1.2 BILLION AS $5.2 BILLION INVESTMENT PROGRAM ACCELERATES ECONOMIC DIVERSIFICATION
Investment activity has drawn growing private-sector participation from the United States, United Arab Emirates, Saudi Arabia, Egypt, China, and India. To date, Future Fund Oman has mobilized approximately $2.1 billion in additional private and foreign capital, including eight large-scale projects developed alongside global investors, banks, funds, and family offices. The fund said the rising leverage ratio reflects strengthening international confidence in Oman’s industrial, manufacturing, and clean energy ambitions.
Job creation remains a key performance indicator. Projects approved since launch have generated more than 1,400 jobs, with thousands more in progress. Investments span five national priority clusters , energy transition, advanced materials, healthcare, logistics, and information and communications technology, reinforcing the fund’s role in shaping the country’s next phase of economic growth.
Flagship developments include a $1.6 billion solar-grade polysilicon manufacturing facility by United Solar, scheduled for completion in 2026. The project has already supported over 1,000 jobs and delivered more than $317 million in in-country value, while also attracting interest from international development finance institutions. Another major project is JA Solar’s six-gigawatt solar cell manufacturing complex in the SOHAR Port and Freezone, a $442 million investment nearing key construction milestones. Once operational, the facility is expected to employ more than 500 people and expand Oman’s foothold in regional clean energy supply chains.
Momentum also continues under the fund’s SME and venture capital mandate. Since inception, 132 SME and VC projects have been approved, with $56.7 million committed and $37.4 million deployed through eight specialized vehicles covering pre-seed, seed, growth equity, and SME debt. Application volumes remain strong across both mandates, driven by sustained domestic and international interest in projects linked to industrial modernization, technology development, and clean energy.
Since launch, the fund has assessed 828 proposals and approved 141 projects valued at around $3.4 billion, spanning nine major strategic investments and 132 SME and venture capital initiatives. Its dual mandate guides capital toward both large national projects and smaller high-growth businesses, with a targeted 12 percent return and a 40 percent equity ceiling per investment.
OTTAWA, ON, Dec. 17, 2025 – New Canadian technology company Woodway Assurance is proud to announce that it has closed an oversubscribed seed funding round for its flagship product, EviData™, raising $1 million. This shows strong investor conviction that independent, standards-aligned and automated data assurance is becoming a necessary layer for data-driven organizations, and confidence that Woodway’s management team, with its deep experience in researching, developing and commercializing privacy enhancing technologies, is well positioned to deliver it. The round was led by Aventure Capital, with participation from other angel investors.
“EviData addresses a growing pain point for organizations trying to clear roadblocks to responsible data use. I was very impressed with the vision for this transformative product, its significant potential and the plans for bringing it to market,” said Aventure Capital co-founder Frederic Boulanger. “We expect the solution to become an essential layer in the modern data stack.”
Organizations across health and life sciences, financial services and other sectors depend on data for research, analytics and AI projects, but they are under growing pressure to prove that their de-identification practices can stand up to scrutiny. When organizations, partners or clients don’t have the technical expertise to verify claims that datasets are properly de-identified, decisions can stall or default to a “no.” EviData is the first-of-its-kind software solution designed to turn that into a managed and defensible “yes” so data can be accessed, used and shared responsibly.
Running inside the client’s environment and requiring minimal expertise, EviData uses AI-driven automation to assess an uploaded de-identified or synthetic dataset for privacy and utility. Within minutes it generates a clear, auditable third-party report with documented and reliable evidence of whether a dataset can be treated as non-personal information, mapped to guidance from Canadian regulators and the ISO standards.
“It’s no longer enough for data teams to say they protect privacy. They now have to prove they’re meeting contemporary standards,” said Dr. Khaled El Emam, founder and CEO of Woodway Assurance, Canada Research Chair in Medical AI at the University of Ottawa. “This funding will help us reach more organizations that need a practical way to comply with privacy rules and show with independent evidence that their data can be trusted, so they can get faster approvals without losing data utility. EviData makes that assurance fast, repeatable and reliable so teams can keep innovating with their data and AI projects.”
Woodway Assurance launched in early fall 2025, EviData is already in market and being deployed with early customers to support research, analytics and product development across multiple data-intensive sectors, and the company is already generating revenue. The new funding will help accelerate the company’s growth by building out its capacity in sales, marketing and customer success, and by continuing to enhance the technological capabilities of EviData that are helping organizations scale de-identification assurance across projects.
Built on Google Cloud infrastructure, Drive Health is expanding Avery’s clinical workflow and operational capabilities, building toward broader health system and health plan deployment and a planned Series A in 2026.
MIAMI, Dec. 17, 2025 — Vitalis Ventures, an investment platform focused on AI enabled healthcare technology companies advancing next-generation care delivery, announces a strategic $15 million investment in Drive Health, the healthcare technology company behind Avery, a Google-powered agentic AI platform designed to transform how patients navigate care and alleviate the workload placed on clinicians. The total investment includes an additional tranche scheduled to close in Q1 2026. Vitalis Ventures partnered with Inside Capital Partners on the transaction.
avery ipad (PRNewsfoto/Vitalis)
This latest investment from Vitalis Ventures brings the total capital committed to Drive Health to $26+ million. The funding marks a significant step in Drive Health’s expansion as the company looks toward a Series A in 2026 and continues to advance its collaboration with Google to deliver scalable, clinically aligned AI support across health systems, managed care organizations and population health plans. Upon completion of the second tranche, Vitalis Ventures will join Drive Health’s Board of Directors, with a focus on strengthening and developing partnerships throughout the healthcare ecosystem.
“This partnership marks a major inflection point for Drive Health,” said Kevin Longoria, CEO of Drive Health. “Vitalis brings real operational depth, health-system experience, and the long-term vision needed to scale Avery responsibly. With their support, and through our continued work with Google, we are accelerating our ability to deliver safe, accessible, and compassionate AI support to healthcare facilities and patients nationwide.”
“Drive Health developed the lowest latency, most comprehensive and clinically aligned workflow automation platform in the market, with the potential to meaningfully reshape how care teams manage communication and follow-up,” said Elliot LaBreche, Founder and CEO of Vitalis. “We believe Avery’s approach to continuity-of-care represents the future of patient support, and we are proud to partner with the Drive Health team as they scale the platform nationwide.”
Avery is Drive Health’s flagship AI-enabled clinical workflow engine, built to support nurses and care teams in managing high-volume communication, education, and coordination tasks with patients and families. Avery automates well-defined units of work such as discharge orchestration, secure-message triage, and follow-up outreach, operating under hospital-defined rules and risk caps.
Integrated directly into clinical workflows, Avery can draft and deliver clinician-approved education, collect symptom and adherence information, and route issues for review based on safe escalation criteria across episodes like pregnancy, chronic disease management, and post-discharge recovery. By handling routine questions and administrative tasks under strict human oversight, Avery helps healthcare providers operate more efficiently while allowing doctors and nurses to focus their expertise on high-touch, in-person care.
Avery is designed to support, not replace, the judgment of licensed clinicians. It does not independently diagnose, treat, or prescribe, and every workflow runs with human-in-the-loop controls, audit logging, and safety governance.
Backed by Google and built on Google Cloud’s healthcare-grade infrastructure, Avery can communicate in more than 15 languages and operate with enterprise-level security, speed, and scale. Beginning in 2024, Drive Health and Google partnered to deepen Avery’s contextual reasoning, cybersecurity, enterprise scalability, and health-system integration, a collaboration that positions Avery as one of the most advanced AI solutions entering the market today. To ensure Avery evolves in step with clinical needs, safety and regulatory standards, the platform is developed in close collaboration with front-line nurses and clinicians through Drive Health’s Clinical Advisory Council. Drive Health also maintains a Clinical Safety Committee which brings interprofessional voices to AI governance and patient-safety.
With this latest capital commitment, Drive Health gains strategic funding and the opportunity to leverage Vitalis’ deep experience partnering with healthcare systems. This expertise in patient flow, operational bottlenecks, and workforce challenges will help Drive Health accelerate deployment and adoption across payers and providers.
Drive Health and Google are also supporting the State of Illinois’ Healthy Baby initiative, a multi-year program aimed at improving maternal and infant outcomes in underserved communities. The initiative will support more than 56,000 participating families with Google Pixel devices, Fitbit technology, and AT&T connectivity, while Avery delivers clinician-approved education, appointment reminders, and structured symptom check-ins from pregnancy through postpartum under the supervision of clinicians.
As Drive Health prepares for its upcoming Series A, the company plans to expand Avery into additional care pathways, explore innovative regulatory approaches, deepen health system integrations, and grow its team of clinical experts guiding the evolution of the platform, with the long-term goal of making continuous access to care available to every patient, everywhere.
About Drive Health
Drive Health turns AI workflows into audited clinical systems where every action is measured, governed, and proven. Avery, Drive Health’s clinical workflow engine, automates well-defined nursing and care-team tasks like discharge orchestration, secure-message triage, and rounding follow-up. Avery is designed to support, not replace, the judgment of licensed clinicians. It does not independently diagnose, treat, or prescribe. Each workflow operates under hospital-defined risk caps, human-in-the-loop controls, and continuous monitoring for safety and performance review. For more information, visit DriveHealth.ai.
About Vitalis
Vitalis Ventures invests in AI-enabled healthcare technology companies to improve access, quality, and efficiency across the U.S. health system. Their thesis is informed by years of operating a portfolio of outpatient medical, surgery center and behavioral health facilities, which gives the team a unique understanding of how patients move through the health system, where bottlenecks occur, and how technology can increase efficiencies & reduce cost. Vitalis Ventures backs companies that solve the industry’s most urgent structural challenges—most notably the nationwide labor shortage, diagnostic delays, gaps in care coordination, and rising costs. To learn more about Vitalis, visit https://vitalisventures.ai/.
About Inside Capital Partners
Inside Capital Partners (“INSIDE”) is a Venture Growth Fund focused on investing in and scaling innovative AI and deep health tech solutions. By leveraging deep relationships with health systems, industry leaders, government entities, and domestic as well as international partners, INSIDE unlocks significant value for companies, health systems, and the overall U.S. healthcare market. To learn more about INSIDE, visit: https://insidecapitalpartners.com/
APPLETON, Wis., Dec. 17, 2025 — Global Alternative Investment Management LLC (“Global Alts“) is pleased to announce the launch of Global Alts LLC – Unicorn Tech Fund III (the “Fund“), a new private investment vehicle designed to provide qualified investors with access to late-stage, high-growth technology companies—commonly known as “unicorns”—that we believe are reshaping global markets.
Unicorn Tech Fund III represents the next evolution of Global Alts’ longstanding thematic focus on transformative technology investments, building on the management team’s prior Unicorn Tech Fund I and II strategies. The investment objective of the Fund is to opportunistically acquire a diversified portfolio of private technology companies and complementary venture funds pursuing or benefitting from disruptive innovation from artificial intelligence and related technologies.
Since its 2021 spinout from its affiliate, Endowment Wealth Management, Inc., Global Alts has collaborated on raising six prior funds, deploying nearly $40 million across a broad array of alternative assets, including late-stage technology venture capital, financial technology, blockchain infrastructure, and sector-specific co-investment strategies. In 2024, Global Alts closed a single-purpose fund targeting an investment in Groq, a pioneering AI infrastructure company that completed a $640 million Series D round led by BlackRock Private Equity Partners.
Strategic Opportunity in Developing Technology Markets “With Unicorn Tech Fund III, we are expanding upon our curated approach to sourcing what we believe to be unique private technology opportunities,” said Prateek Mehrotra, MBA, CFA, CAIA®, Chief Investment Officer. “The private technology ecosystem remains rich with innovation, and we believe as generative AI and other technologies evolve, they may have the potential to further disrupt industries and create sustained growth opportunities.” We believe our deep network of venture capital relationships positions us to identify companies solving complex problems with scalable business models.”
The Firm believes that structural shifts—such as the rapid adoption of AI, automation, cloud modernization, and digital identity technologies—continue to generate significant need for mid to late-stage private capital and provide potential opportunities for investors seeking to participate in them.
Building on a History of Thematic Fund Management “Unicorn Tech Fund III is a natural extension of our investment philosophy and the evolution of our private fund business,” added Robert Riedl, CPA, CFP®, AWMA®, Managing Member. “High-net-worth investors are increasingly seeking access to private market opportunities that they cannot source through traditional channels. Our dedicated fund platform allows us to deliver these opportunities while maintaining the personalized, high-touch experience that our investors value.”
About Global Alternative Investment Management LLC Global Alts is a private fund management company that creates and markets private funds for Accredited Investors, Qualified Clients, and Qualified Purchasers, as well as institutional and nonprofit investors. The Firm focuses on opportunistic investments across global private markets, including venture capital, private equity, secondary transactions, and bespoke co-investment structures. Its investment team has a 25+ year track record of evaluating and accessing differentiated alternative investment opportunities worldwide.
Prateek Mehrotra, MBA, CFA, CAIA® Managing Member, Chief Investment Officer Global Alternative Investment Management LLC [email protected] 920.785.6009
Robert Riedl, CPA, CFP®, AWMA® Managing Member Global Alternative Investment Management LLC [email protected] 920.785.6011
Important Disclosures This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to purchase any security, fund interest, or investment product. Interests in Global Alts LLC – Unicorn Tech Fund III (the “Fund”) will be offered solely pursuant to a confidential private placement memorandum (the “Memorandum”), which will be furnished exclusively to Accredited Investors, Qualified Clients, and Qualified Purchasers on a confidential basis and only in jurisdictions where such offerings are permitted by law. Investors should review the Memorandum carefully and consider their ability to bear the risks described therein. No assurance can be given that the Fund will achieve its investment objectives or that any investor will receive a return of capital.
There are a significant number of factors that could cause the actual benefits and expectations with respect to the fund to differ materially from the statements made in this press release, including the ability to identify and manage investment opportunities. An investment in the Fund involves significant risks, including the potential loss of all capital invested. Private investments are speculative, illiquid, involve the substantial risk of loss including loss of all capital invested. An investment in the fund is not suitable for all investors. Additional information regarding risks associated with alternative investments is available atwww.GlobalAlts.com.
Any references to prior funds or investments are provided for illustrative purposes only and do not represent, and should not be interpreted as, an indication of future performance. You should not assume that any of the above content serves as the receipt of, or as a substitute for personalized investment advice. Investors should consult with their financial and tax advisors before considering an investment.
Global Alts relies upon the investment adviser registration of Endowment Wealth Management, Inc. based on certain no-action letters issued to the American Bar Association in the past. The activities of Global Alts’ investment advisory activities are subject to the Investment Advisers Act of 1940 and the rules thereunder and is subject to examination by the Securities and Exchange Commission.
This communication may be deemed to be an advertisement under Rule 206(4)-1 of the Investment Advisers Act of 1940. Any statements contained herein reflect the opinions, beliefs, or views of Global Alternative Investment Management LLC (“Global Alts”) as of the date hereof and are subject to change without notice. Certain information contained herein constitutes forward-looking statements, which are inherently uncertain and involve risks and assumptions. Actual results may differ materially. Global Alts makes no representation or warranty as to the accuracy or completeness of the information contained herein and undertakes no obligation to update or revise such information.
SOURCE Global Alternative Investment Management LLC
